NCT03437941 - Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2017

Primary Completion Date

January 9, 2023

Study Completion Date

January 9, 2023

Conditions

Metastatic Castration-Resistant Prostate Cancer

Interventions

DRUG

CORT125281

CORT125281 is supplied as capsules for oral dosing

DRUG

Enzalutamide (Xtandi)

Enzalutamide will be taken orally

DRUG

Placebo

Placebo capsules to match the appearance of the CORT125281

Trial Locations (8)

New York, New York

Detroit, Detroit

Madison, Madison

Scottsdale, Scottsdale

Portland, Portland

London, London

Southampton, Southampton

Sutton, Sutton